{"id":"toripalimab-plus-concurrent-chemo-radiotherapy","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Fatigue"},{"rate":"20-30%","effect":"Nausea"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Vomiting"},{"rate":"10-20%","effect":"Anemia"},{"rate":"5-10%","effect":"Thrombocytopenia"},{"rate":"5-10%","effect":"Neutropenia"},{"rate":"5-10%","effect":"Leukopenia"}]},"_chembl":{"chemblId":"CHEMBL4297843","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By blocking the PD-1 receptor, toripalimab prevents cancer cells from evading the immune system. This allows the immune system to recognize and attack cancer cells more effectively. Toripalimab is typically used in combination with other treatments, such as chemotherapy and radiation therapy, to enhance its anti-tumor effects.","oneSentence":"Toripalimab is a PD-1 inhibitor that works by blocking the PD-1 receptor on T cells, allowing them to attack cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:39:27.984Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic nasopharyngeal carcinoma, recurrent or metastatic nasopharyngeal carcinoma"},{"name":"Locally advanced or metastatic esophageal squamous cell carcinoma"}]},"trialDetails":[{"nctId":"NCT07362979","phase":"PHASE2","title":"Toripalimab Combined With Different Platinum-Based Induction Chemotherapy Regimens for Locally Advanced Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-03-12","conditions":"Nasopharyngeal Cancinoma (NPC)","enrollment":243},{"nctId":"NCT06719700","phase":"PHASE2","title":"Concurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-11-30","conditions":"Toripalimab, Surufatinib, Chemoradiotherapy","enrollment":47},{"nctId":"NCT06208826","phase":"PHASE2","title":"A Single-center Phase II Study to Investigate the Immune Maintenance Therapy Pattern in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Who Have Achieved MPR After Neoadjuvant Immunotherapy Combined With Chemotherapy","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2023-09-01","conditions":"Head and Neck Cancer","enrollment":268},{"nctId":"NCT05888402","phase":"PHASE2","title":"Induction Chemotherapy and Toripalimab Followed by Chemoradiotherapy for Large-volume Local Advanced NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2023-01-20","conditions":"Local Advanced Non-small Cell Lung Cancer","enrollment":50},{"nctId":"NCT07423078","phase":"PHASE2","title":"Window of Opportunity in Preserving Laryngeal Function Trial","status":"NOT_YET_RECRUITING","sponsor":"Matthew Spector","startDate":"2026-03-31","conditions":"Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Locally Advanced Laryngeal Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma","enrollment":87},{"nctId":"NCT07410234","phase":"PHASE2","title":"Phase II Exploratory Study of Toripalimab Combined With SBRT in HER2-Negative Breast Cancer Patients With Insensitivity to Neoadjuvant Chemotherapy","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2026-02-21","conditions":"Breast Cancer","enrollment":110},{"nctId":"NCT06592599","phase":"PHASE2","title":"Gemcitabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Associated Nasopharyngeal Carcinoma(NPC)","status":"RECRUITING","sponsor":"Stanford University","startDate":"2024-09-03","conditions":"Nasopharyngeal Carcinoma","enrollment":24},{"nctId":"NCT07214987","phase":"PHASE2","title":"PDT For Induction Therapy For Head And Neck Cancer","status":"NOT_YET_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2026-03-09","conditions":"Squamous Cell Carcinoma, Head and Neck Cancer Squamous Cell Carcinoma, Head and Neck Cancer","enrollment":26},{"nctId":"NCT07371897","phase":"PHASE3","title":"Toripalimab ± Chemo as Neoadjuvant Therapy in LA-HNSCC: A Phase III Trial","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-06-30","conditions":"Head and Neck Squamous Cell Carcinoma HNSCC","enrollment":154},{"nctId":"NCT07340515","phase":"PHASE3","title":"Proton vs Photon IMRT in Locally Advanced Nasopharyngeal Carcinoma: A Phase III Trial","status":"RECRUITING","sponsor":"Man Hu","startDate":"2025-12-15","conditions":"Nasopharyngeal Carcinoma (NPC)","enrollment":300},{"nctId":"NCT07328841","phase":"PHASE3","title":"Reduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngeal Carcinoma With Remission After Induction Chemotherapy and Immunotherapy","status":"RECRUITING","sponsor":"Ming-Yuan Chen","startDate":"2025-11-18","conditions":"Nasopharyngeal Carcinoma (NPC)","enrollment":456},{"nctId":"NCT06416696","phase":"PHASE2","title":"Toripalimab for High-risk Locally Advanced Cervical Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2024-01-09","conditions":"Cervical Cancers","enrollment":57},{"nctId":"NCT07279597","phase":"PHASE2","title":"A Phase II Study of Toripalimab Plus RC48-ADC With Radiotherapy for Bladder Preservation in HER2-Positive Muscle-Invasive Bladder Cancer","status":"NOT_YET_RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-12-10","conditions":"Muscle-invasive Bladder Urothelial Carcinoma","enrollment":45},{"nctId":"NCT05975307","phase":"PHASE2","title":"Treating Muscle-invasive Bladder Cancer With A Non-surgical Method Consisting of Anti-PD-1 Therapy and Chemoradiation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-12-01","conditions":"Muscle-Invasive Bladder Carcinoma, Programmed Cell Death Protein 1 Inhibitor, Radiotherapy","enrollment":71},{"nctId":"NCT07235319","phase":"PHASE3","title":"PD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Salvage Locoregional Radiotherapy in De Novo Metastatic NPC","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-11-20","conditions":"Nasopharangeal Cancer, Distant Metastasis","enrollment":260},{"nctId":"NCT07236320","phase":"NA","title":"Neoadjuvant Immunochemotherapy vs Chemoradiotherapy in ESCC","status":"COMPLETED","sponsor":"Yongtao Han","startDate":"2018-03-01","conditions":"Esophageal Squamous Cell Carcinoma (ESCC)","enrollment":200},{"nctId":"NCT07086469","phase":"PHASE2","title":"Surufatinib in Combination With Neoadjuvant Chemo-immunotherapy and Concurrent Chemoradiotherapy for Patients With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-07-20","conditions":"Toripalimab, Surufatinib, Neoadjuvant Immunochemotherapy","enrollment":69},{"nctId":"NCT06912074","phase":"PHASE2","title":"Hypofractionated vs. Conventional Chemoradiotherapy After Induction Chemo-immunotherapy for Unresectable Esophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-04-05","conditions":"Esophageal Squamous Cell Carcinoma (ESCC)","enrollment":134},{"nctId":"NCT06281886","phase":"PHASE2","title":"Induction Immuno-chemotherapy and Concurrent Chemoradiotherapy With or Without Apatinib in Unresectable, Locally Advanced Esophageal Squamous Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-12-01","conditions":"Esophageal Squamous Cell Carcinoma, Efficacy, Toxicity","enrollment":170},{"nctId":"NCT05386888","phase":"PHASE2","title":"A Trial of GFH018 and Toripalimab in Combination With Concurrent Chemoradiotherapy in Stage III NSCLC Chemoradiotherapy in Stage III NSCLC","status":"COMPLETED","sponsor":"Genfleet Therapeutics (Shanghai) Inc.","startDate":"2022-09-09","conditions":"NSCLC, Stage III","enrollment":65},{"nctId":"NCT07092696","phase":"PHASE2","title":"Induction Immunotherapy Combined With Chemotherapy Followed by Concurrent Chemoradiotherap and Immunotherapy for Cervical Cancer","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2024-12-01","conditions":"Cervical Cancer","enrollment":34},{"nctId":"NCT06020885","phase":"PHASE1","title":"Fraction Dose Escalation of Split-course Hypofractionated Concurrent Chemoradiotherapy Following Induction Chemo-immunotherapy in Unresectable Locally Advanced Esophageal Squamous Carcinoma: a Phase I Study.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-08-31","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":18},{"nctId":"NCT04907370","phase":"PHASE3","title":"PD-1 Blockade Combined With De-intensified Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2021-08-01","conditions":"Nasopharyngeal Carcinoma","enrollment":532},{"nctId":"NCT06605131","phase":"PHASE2","title":"GP Combined with Toripalimab Versus GP Induction Chemotherapy for Advanced Childhood Nasopharyngeal Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-04-17","conditions":"Nasopharyngeal Cancinoma (NPC)","enrollment":72},{"nctId":"NCT06712888","phase":"PHASE3","title":"Toripalimab Vs. Placebo Wtih GP Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-02-17","conditions":"Nasopharyngeal Carcinoma (NPC)","enrollment":466},{"nctId":"NCT04365036","phase":"PHASE3","title":"A Multicenter, Phase 3, Randomized Trial of Sequencial Chemoradiotherapy with or Without Toripalimab (PD-1 Antibody) in Newly Diagnosed Early-Stage Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (ENKTL)","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2020-05-03","conditions":"NK/T Cell Lymphoma Nos","enrollment":207},{"nctId":"NCT06851247","phase":"PHASE2","title":"GAPP Induction and Concurrent Chemoradiotherapy Followed by Toripalimab Maintenance for Nasopharyngeal Carcinoma.","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-01-03","conditions":"Nasopharyngeal Carcinoma","enrollment":47},{"nctId":"NCT06762158","phase":"NA","title":"NCRT Combined With Sequential Perioperative PD-1 Inhibitor for LAESCC","status":"ACTIVE_NOT_RECRUITING","sponsor":"RenJi Hospital","startDate":"2024-10-30","conditions":"Esophageal Squamous Cell Carcinoma (ESCC)","enrollment":50},{"nctId":"NCT06732258","phase":"PHASE1","title":"Low-dose Radiotherapy Combined with Concurrent Chemotherapy, Toripalimab and Tifcemalimab in the Treatment of ES-SCLC","status":"NOT_YET_RECRUITING","sponsor":"Sichuan University","startDate":"2025-01-10","conditions":"Extensive-stage Small-cell Lung Cancer","enrollment":12},{"nctId":"NCT05060471","phase":"PHASE2","title":"PD-1 Blockade Combined with Chemotherapy Followed by Concurrent Immunoradiotherapy for Locally Advanced SCCA Patients","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2021-10-27","conditions":"Anal Canal Cancer, Anal Squamous Cell Carcinoma, Anal Cancer","enrollment":25},{"nctId":"NCT06675214","phase":"PHASE3","title":"Under Whole-course of Immunotherapy, Gradient Fractionated RT with CCT Versus CFRT with CCT for LANPC Who Achieved PR Post Induction Chemotherapy.","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-07-30","conditions":"Nasopharyngeal Carcinoma, De-escalation Therapy","enrollment":586},{"nctId":"NCT06462053","phase":"PHASE2","title":"Short-course Radiotherapy Combined With CAPOX and PD-1 Antibody Versus Long-course Chemoradiotherapy Combined With CAPOX for Early Low-lying Rectal Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-04-01","conditions":"Early Low Rectal Cancer","enrollment":134},{"nctId":"NCT06151743","phase":"PHASE2","title":"Neoadjuvant PD-1 Inhibitor Combined With Cetuximab and Platinum in Resectable Locally Advanced Hypopharyngeal Carcinoma","status":"RECRUITING","sponsor":"Eye & ENT Hospital of Fudan University","startDate":"2024-01-18","conditions":"Locally Advanced Hypopharyngeal Carcinoma","enrollment":32},{"nctId":"NCT06256224","phase":"NA","title":"Toripalimab Combined With Definitive CCRT for LACC Patients","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2024-02-02","conditions":"Cervical Cancer, Chemoradiotherapy, Immunotherapy","enrollment":150},{"nctId":"NCT06187597","phase":"PHASE2","title":"Consolidation of Toripalimab After Chemoradiotherapy in Elderly Esophageal Cancer (EC-CRT-007)","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-03-01","conditions":"Locally Advanced Esophageal Squamous Cell Carcinoma","enrollment":140},{"nctId":"NCT04844385","phase":"PHASE2","title":"Toripalimab Plus Neoadjuvant Chemotherapy Combined With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2021-02-20","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":124},{"nctId":"NCT06092957","phase":"PHASE3","title":"Reduced-dose RT With/Without CCT Versus Standard CCRT for High-risk LANPC Who Achieved CR Post Induction Chemotherapy","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-10-09","conditions":"Nasopharyngeal Carcinoma, De-escalation Therapy","enrollment":504},{"nctId":"NCT06156891","phase":"PHASE2","title":"PD-1 Inhibitor Based Induction Chemotherapy Followed by De-escalation Protocols in OPSCC","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2022-06-29","conditions":"Oropharyngeal Cancer","enrollment":60},{"nctId":"NCT06080854","phase":"PHASE2","title":"AG Combined With Immunotherapy and SBRT in Patients With Potentially Resectable Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2023-11-10","conditions":"Pancreatic Carcinoma","enrollment":108},{"nctId":"NCT06039631","phase":"PHASE2","title":"Neoadjuvant Chemoimmunotherapy Followed By Radiation Or Organ Preservation Surgery In Laryngeal/Hypopharyngeal Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2023-08-22","conditions":"Larynx Cancer, Hypopharyngeal Cancer","enrollment":82},{"nctId":"NCT03925090","phase":"PHASE2","title":"Phase II Trial of Neoadjuvant and Adjuvant Anti-PD-1 Antibody Toripalimab Combined With CCRT in NPC Patients","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2019-12-08","conditions":"Nasopharyngeal Carcinoma","enrollment":150},{"nctId":"NCT05424432","phase":"PHASE2","title":"Short Course Neoadjuvant Chemo-radiotherapy Plus Toripalimab for Locally Advanced Resectble Squamous Cell Carcinoma of Esophagus","status":"UNKNOWN","sponsor":"Jiangsu Cancer Institute & Hospital","startDate":"2022-04-29","conditions":"Locally Advanced Esophageal Carcinoma","enrollment":63},{"nctId":"NCT05420597","phase":"PHASE2","title":"Induction Chemotherapy and Toripalimab Followed by Radiotherapy in Unresectable Laryngeal/Hypopharyngeal Carcinoma","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2021-04-07","conditions":"Laryngeal Cancer, Hypopharyngeal Cancer","enrollment":61},{"nctId":"NCT04888403","phase":"PHASE2","title":"Exploring the Safety and Effectiveness of Toripalimab Combined With Neoadjuvant Radiotherapy and Chemotherapy in the Locally Advanced Esophageal Squamous Cell Carcinoma","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Zhengzhou University","startDate":"2021-12-31","conditions":"Locally Advanced Esophageal Squamous Cell Carcinoma","enrollment":45},{"nctId":"NCT04867330","phase":"NA","title":"Toripalimab Based Induction Chemotherapy Followed by De-escalation Protocols in HPV-related OPSCC","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2021-02-01","conditions":"Oropharyngeal Carcinoma, Immune Checkpoint Inhibitor, De-escalation","enrollment":46},{"nctId":"NCT04084158","phase":"PHASE2","title":"A Study of Toripalimab Combined With Concurrent Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma.","status":"SUSPENDED","sponsor":"Zhejiang Cancer Hospital","startDate":"2019-09-07","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":100},{"nctId":"NCT04453813","phase":"PHASE3","title":"Toripalimab Plus Concurrent Chemo-radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2020-07-03","conditions":"Nasopharyngeal Carcinoma, Chemotherapy, Radiotherapy","enrollment":226},{"nctId":"NCT04446663","phase":"PHASE2","title":"Toripalimab Combined With Chemoradiotherapy in Patients With Locoregionally-advanced Nasopharyngeal Carcinoma","status":"UNKNOWN","sponsor":"First People's Hospital of Foshan","startDate":"2020-07-15","conditions":"Nasopharyngeal Neoplasms","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Toripalimab plus concurrent chemo-radiotherapy","genericName":"Toripalimab plus concurrent chemo-radiotherapy","companyName":"Sun Yat-sen University","companyId":"sun-yat-sen-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Toripalimab is a PD-1 inhibitor that works by blocking the PD-1 receptor on T cells, allowing them to attack cancer cells. Used for Metastatic nasopharyngeal carcinoma, recurrent or metastatic nasopharyngeal carcinoma, Locally advanced or metastatic esophageal squamous cell carcinoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}